Peter Voorhees, MD

Cristina Gasparetto, MD, details how to assess treatment response and duration of treatment for transplant-eligible NDMM.

Dr Cindy Varga explains the design and results of the MASTER study presented at ASH [American Society of Hematology Annual Meeting] 2021.

Cindy Varga, MD, presents a profile of a 59-year-old patient diagnosed with transplant-eligible multiple myeloma.

The panel discusses triplet and quadruplet regimen options for transplant-eligible NDMM, and the clinical implications of the DETERMINATION study.

Experts in the multiple myeloma field discuss which front-line therapy is best for patients who are treatment ineligible.

After reviewing implications of the MAIA study in multiple myeloma, experts consider unmet needs and future directions in care.

Panelists discuss the case of a 77-year-old man with newly diagnosed multiple myeloma who wishes to discontinue therapy after achieving a very good partial response.

Experts review the case of a 75-year-old woman with newly diagnosed multiple myeloma and discuss treatment selection, continuation, reduction, and duration.

In-depth considerations for available frontline therapy regimens for patients with transplant-ineligible multiple myeloma.

A panel of experts reflects on appropriate actions to take after a patient achieves adequate response to therapy for transplant-ineligible multiple myeloma.

Shared insight on how best to assess a patient’s response to therapy for transplant-ineligible multiple myeloma.

Panelists elucidate how to determine transplant ineligibility and the goals of therapy while managing a patient with multiple myeloma.

Shared insight on the difficulties of transplant-ineligible newly diagnosed multiple myeloma and how to optimally approach treatment.

The myeloma expert discussed the importance of sustained MRD negativity for patients with multiple myeloma treated with daratumumab (Darzalex).

The expert from the Levine Cancer Institute discussed the findings from an updated analysis of the phase 2 GRIFFIN Trial for patients with newly diagnosed multiple myeloma.

Voorhees noted that despite challenges associated with the COVID-19 pandemic, emerging therapies offer hope for patients with multiple myeloma.

The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma.